Basiliximab
Authors:
- 1 February 2010
- journal article
- review article
- Published by Springer Nature in BioDrugs
- Vol. 24 (1) , 55-76
Abstract
Basiliximab (Simulect®) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody that is indicated for the prevention of acute organ rejection in adult and pediatric renal transplant recipients in combination with other immunosuppressive agents. Induction therapy with two doses (day 0 and day 4) of intravenous basiliximab as part of double- or triple-immunotherapy regimens in adult renal transplant recipients reduces acute rejection episodes without increasing the incidence of adverse events. Compared with rabbit-derived antithymocyte globulin (RATG), basiliximab is generally associated with similar efficacy in standard-risk patients, but reduced efficacy in high-risk patients. Initial results indicate that induction with basiliximab is associated with a higher rate of biopsy-proven acute rejection than alemtuzumab induction. Basiliximab is generally associated with a tolerability profile that is similar to that reported with placebo, and better than that reported with RATG. As with other induction agents, basiliximab has not demonstrated improved graft or patient survival over the long term (periods of up to 7 years). Basiliximab induction allows for reduced dosage of corticosteroids or calcineurin inhibitors, while maintaining adequate immunosuppression, thereby reducing the potential for adverse effects associated with these coadministered agents. Thus, basiliximab provides an effective, well tolerated option for the prophylaxis of acute renal transplant rejection.Keywords
This publication has 96 references indexed in Scilit:
- Early Outcomes of Thymoglobulin and Basiliximab Induction in Kidney TransplantationTransplantation, 2009
- Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up dataPediatric Nephrology, 2009
- Minimization of steroids in kidney transplantationTransplant International, 2008
- A Randomized, Multicenter Study of Steroid Avoidance, Early Steroid Withdrawal or Standard Steroid Therapy in Kidney Transplant RecipientsAmerican Journal of Transplantation, 2008
- Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimenTransplant Immunology, 2008
- Randomized Controlled Study Comparing Reduced Calcineurin Inhibitors Exposure Versus Standard Cyclosporine-Based ImmunosuppressionTransplantation, 2007
- Alemtuzumab Induction and Prednisone‐Free Maintenance Immunotherapy in Kidney Transplantation: Comparison with Basiliximab Induction—Long‐Term ResultsAmerican Journal of Transplantation, 2005
- A Multicenter Pilot Study of Early (4-Day) Steroid Cessation in Renal Transplant Recipients Under Simulect, Tacrolimus and SirolimusAmerican Journal of Transplantation, 2005
- Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine‐based immunosuppression and protocol biopsiesClinical Transplantation, 2004
- BasiliximabDrugs, 2003